亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Lenacapavir administered every 26 weeks or daily in combination with oral daily antiretroviral therapy for initial treatment of HIV: a randomised, open-label, active-controlled, phase 2 trial

恩曲他滨 医学 替诺福韦-阿拉芬酰胺 加药 内科学 养生 病毒载量 人类免疫缺陷病毒(HIV) 抗逆转录病毒疗法 病毒学
作者
Samir Kumar Gupta,Mezgebe Berhe,Gordon E. Crofoot,Paul M. Benson,Moti N. Ramgopal,James Sims,Cheryl McDonald,Peter Jerome Ruane,William E. Sanchez,Anita Scribner,Shanyu Liu,Laurie A. VanderVeen,Hadas Dvory‐Sobol,Martin S. Rhee,Jared M. Baeten,Ellen Koenig
出处
期刊:The Lancet HIV [Elsevier BV]
卷期号:10 (1): e15-e23 被引量:114
标识
DOI:10.1016/s2352-3018(22)00291-0
摘要

Antiretroviral agents with novel mechanisms and dosing intervals could expand treatment options for people with HIV. Lenacapavir, an inhibitor of capsid protein that makes use of a unique mechanism, can be administered orally or subcutaneously. We sought to explore the efficacy of lenacapavir in various combination regimens as initial and maintenance therapy for HIV.In a phase 2, randomised, open-label, ongoing study at 41 investigational sites in the USA and Dominican Republic, we randomly assigned adults with HIV who had not previously received antiretrovirals to four groups (2:2:2:1). Randomisation was stratified by plasma HIV-1 RNA load (≤100 000 or >100 000 copies per mL) at screening. Groups 1 and 2 both received lenacapavir (927 mg) subcutaneously every 26 weeks (after 2 weeks of oral loading [600 mg on days 1 and 2, followed by 300 mg on day 8]) with oral daily emtricitabine (200 mg) and tenofovir alafenamide (25 mg) for 28 weeks followed by subcutaneous lenacapavir (927 mg) plus oral daily tenofovir alafenamide (25 mg, group 1) or bictegravir (75 mg, group 2). Group 3 received oral daily lenacapavir (600 mg on days 1 and 2, followed by 50 mg daily) with emtricitabine (200 mg) and tenofovir alafenamide (25 mg). Group 4 received oral daily bictegravir (50 mg), emtricitabine (200 mg), and tenofovir alafenamide (25 mg). Participants and investigators were not masked to group assignment. The primary endpoint was the percentage of participants with virological suppression (HIV-1 RNA <50 copies per mL) at week 54, analysed in the full analysis set (all randomly assigned participants who received at least one dose of study drug) using only on-treatment data. The safety outcome measures were incidences of treatment-emergent adverse events and graded laboratory abnormalities, analysed in the full analysis set. This study is registered at ClinicalTrials.gov, NCT04143594.Between Nov 22, 2019, and Aug 27, 2020, 249 people with HIV were screened, 183 participants were randomly assigned and 182 received a dose of antiretroviral drugs (52 in group 1, 53 in group 2, 52 in group 3, and 25 in group 4). 22 participants did not complete the full study course (five in group 1, 12 in group 2, four in group 3, and one in group 4). At week 54, virological suppression was 90% (47 of 52 patients) for group 1 (difference vs group 4: -2·6%, 95% CI -18·4 to 13·2), 85% (45 of 53) for group 2 (-7·1%, -23·4 to 9·3), 85% (44 of 52) for group 3 (-7·2%, -23·5 to 9·1), and 92% (23 of 25) for group 4. The most frequent non-injection-site adverse events with lenacapavir (subcutaneous or oral) were headache (13%, 21 of 157) and nausea (13%, 21 of 157). The most common lenacapavir-related injection-site reactions were erythema (27%, 28 of 105), swelling (23%, 24 of 105), and pain (19%, 20 of 105), which were generally mild or moderate. No serious adverse event related to study treatment occurred. Three participants discontinued subcutaneous lenacapavir because of grade 1 injection-site reactions (two for induration and one for erythema or swelling).Lenacapavir warrants further investigation as a potential antiretroviral used orally and as injection in combination with other antiretroviral drugs.Gilead Sciences.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
专一的思菱完成签到,获得积分10
7秒前
Maestro_S的应助被科研通管家采纳,获得10
9秒前
9秒前
17秒前
30秒前
zhengjia发布了新的文献求助30
34秒前
动听的山槐完成签到,获得积分10
34秒前
孝顺的怜寒完成签到,获得积分10
34秒前
40秒前
1分钟前
深情安青的应助被zhengjia采纳,获得10
1分钟前
能干的孱完成签到,获得积分10
1分钟前
JiaxinChen完成签到 ,获得积分10
1分钟前
满意的楷瑞完成签到,获得积分10
1分钟前
陆上飞完成签到,获得积分10
1分钟前
1分钟前
1分钟前
游标卡尺发布了新的文献求助10
1分钟前
含蓄的觅波完成签到,获得积分10
1分钟前
彭于晏的应助被游标卡尺采纳,获得10
2分钟前
Owen的应助被笑点低听枫采纳,获得10
2分钟前
2分钟前
个性鹭洋完成签到,获得积分10
2分钟前
昌莆完成签到 ,获得积分10
2分钟前
2分钟前
安静的卿完成签到,获得积分10
2分钟前
滕皓轩完成签到 ,获得积分20
2分钟前
3分钟前
3分钟前
游标卡尺发布了新的文献求助10
3分钟前
顾矜的应助被游标卡尺采纳,获得10
3分钟前
呆萌保温杯完成签到,获得积分10
3分钟前
3分钟前
踏实的元蝶完成签到,获得积分10
3分钟前
Mario发布了新的文献求助10
3分钟前
3分钟前
英俊的铭的应助被ZZWZHENG采纳,获得50
3分钟前
Sunny完成签到,获得积分10
3分钟前
lzl008完成签到 ,获得积分0
3分钟前
3分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8179956
求助须知:如何正确求助?哪些是违规求助? 9570159
关于积分的说明 21808414
捐赠科研通 7775796
什么是DOI,文献DOI怎么找? 3433231
关于科研通互助平台的介绍 2557352
邀请新用户注册赠送积分活动 2478935